Cargando…

Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer

BACKGROUND: Despite major advances in lung cancer treatment, early detection remains the most promising way of improving outcomes. To detect lung cancer in earlier stages, many serum biomarkers have been tested. Unfortunately, no single biomarker can reliably detect lung cancer. We combined a set of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Ho Il, Kwon, Oh-Ran, Kang, Kyung Nam, Shin, Yong Sung, Shin, Ho Sang, Yeon, Eun Hee, Kwon, Keon Young, Hwang, Ilseon, Jeon, Yoon Kyung, Kim, Yongdai, Kim, Chul Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Cancer Prevention 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051593/
https://www.ncbi.nlm.nih.gov/pubmed/27722145
http://dx.doi.org/10.15430/JCP.2016.21.3.187
_version_ 1782458106859487232
author Yoon, Ho Il
Kwon, Oh-Ran
Kang, Kyung Nam
Shin, Yong Sung
Shin, Ho Sang
Yeon, Eun Hee
Kwon, Keon Young
Hwang, Ilseon
Jeon, Yoon Kyung
Kim, Yongdai
Kim, Chul Woo
author_facet Yoon, Ho Il
Kwon, Oh-Ran
Kang, Kyung Nam
Shin, Yong Sung
Shin, Ho Sang
Yeon, Eun Hee
Kwon, Keon Young
Hwang, Ilseon
Jeon, Yoon Kyung
Kim, Yongdai
Kim, Chul Woo
author_sort Yoon, Ho Il
collection PubMed
description BACKGROUND: Despite major advances in lung cancer treatment, early detection remains the most promising way of improving outcomes. To detect lung cancer in earlier stages, many serum biomarkers have been tested. Unfortunately, no single biomarker can reliably detect lung cancer. We combined a set of 2 tumor markers and 4 inflammatory or metabolic markers and tried to validate the diagnostic performance in lung cancer. METHODS: We collected serum samples from 355 lung cancer patients and 590 control subjects and divided them into training and validation datasets. After measuring serum levels of 6 biomarkers (human epididymis secretory protein 4 [HE4], carcinoembryonic antigen [CEA], regulated on activation, normal T cell expressed and secreted [RANTES], apolipoprotein A2 [ApoA2], transthyretin [TTR], and secretory vascular cell adhesion molecule-1 [sVCAM-1]), we tested various sets of biomarkers for their diagnostic performance in lung cancer. RESULTS: In a training dataset, the area under the curve (AUC) values were 0.821 for HE4, 0.753 for CEA, 0.858 for RANTES, 0.867 for ApoA2, 0.830 for TTR, and 0.552 for sVCAM-1. A model using all 6 biomarkers and age yielded an AUC value of 0.986 and sensitivity of 93.2% (cutoff at specificity 94%). Applying this model to the validation dataset showed similar results. The AUC value of the model was 0.988, with sensitivity of 93.33% and specificity of 92.00% at the same cutoff point used in the validation dataset. Analyses by stages and histologic subtypes all yielded similar results. CONCLUSIONS: Combining multiple tumor and systemic inflammatory markers proved to be a valid strategy in the diagnosis of lung cancer.
format Online
Article
Text
id pubmed-5051593
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Korean Society of Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-50515932016-10-07 Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer Yoon, Ho Il Kwon, Oh-Ran Kang, Kyung Nam Shin, Yong Sung Shin, Ho Sang Yeon, Eun Hee Kwon, Keon Young Hwang, Ilseon Jeon, Yoon Kyung Kim, Yongdai Kim, Chul Woo J Cancer Prev Original Article BACKGROUND: Despite major advances in lung cancer treatment, early detection remains the most promising way of improving outcomes. To detect lung cancer in earlier stages, many serum biomarkers have been tested. Unfortunately, no single biomarker can reliably detect lung cancer. We combined a set of 2 tumor markers and 4 inflammatory or metabolic markers and tried to validate the diagnostic performance in lung cancer. METHODS: We collected serum samples from 355 lung cancer patients and 590 control subjects and divided them into training and validation datasets. After measuring serum levels of 6 biomarkers (human epididymis secretory protein 4 [HE4], carcinoembryonic antigen [CEA], regulated on activation, normal T cell expressed and secreted [RANTES], apolipoprotein A2 [ApoA2], transthyretin [TTR], and secretory vascular cell adhesion molecule-1 [sVCAM-1]), we tested various sets of biomarkers for their diagnostic performance in lung cancer. RESULTS: In a training dataset, the area under the curve (AUC) values were 0.821 for HE4, 0.753 for CEA, 0.858 for RANTES, 0.867 for ApoA2, 0.830 for TTR, and 0.552 for sVCAM-1. A model using all 6 biomarkers and age yielded an AUC value of 0.986 and sensitivity of 93.2% (cutoff at specificity 94%). Applying this model to the validation dataset showed similar results. The AUC value of the model was 0.988, with sensitivity of 93.33% and specificity of 92.00% at the same cutoff point used in the validation dataset. Analyses by stages and histologic subtypes all yielded similar results. CONCLUSIONS: Combining multiple tumor and systemic inflammatory markers proved to be a valid strategy in the diagnosis of lung cancer. Korean Society of Cancer Prevention 2016-09 2016-09-30 /pmc/articles/PMC5051593/ /pubmed/27722145 http://dx.doi.org/10.15430/JCP.2016.21.3.187 Text en Copyright © 2016 Korean Society of Cancer Prevention This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Yoon, Ho Il
Kwon, Oh-Ran
Kang, Kyung Nam
Shin, Yong Sung
Shin, Ho Sang
Yeon, Eun Hee
Kwon, Keon Young
Hwang, Ilseon
Jeon, Yoon Kyung
Kim, Yongdai
Kim, Chul Woo
Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer
title Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer
title_full Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer
title_fullStr Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer
title_full_unstemmed Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer
title_short Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer
title_sort diagnostic value of combining tumor and inflammatory markers in lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051593/
https://www.ncbi.nlm.nih.gov/pubmed/27722145
http://dx.doi.org/10.15430/JCP.2016.21.3.187
work_keys_str_mv AT yoonhoil diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT kwonohran diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT kangkyungnam diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT shinyongsung diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT shinhosang diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT yeoneunhee diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT kwonkeonyoung diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT hwangilseon diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT jeonyoonkyung diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT kimyongdai diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer
AT kimchulwoo diagnosticvalueofcombiningtumorandinflammatorymarkersinlungcancer